March 5, 2013 - Bayer Healthcare is expanding its global distribution network for the Medrad Intego positron emission tomography (PET) Infusion System through a new distribution agreement with Comecer SPA. Through this agreement, Bayer and Comecer are providing customers with an integrated nuclear medicine solution – combining the clinical administration capabilities of Intego with the Comecer's protection technologies for PET/computed tomography (CT) centers around the world.
According to Doug Descalzi, Bayer Healthcare's senior director of molecular imaging devices, this distribution agreement capitalizes on the strength of both companies. "This arrangement creates an end-to-end solution for customers, from isotope production to radiopharmaceutical infusion. We're pleased to be working with Comecer to not only provide greater patient access to Intego but also to provide comprehensive product solutions to nuclear medicine suites around the world."
Intego is a worldwide market leader in PET/CT, and the only U.S. Food and Drug Administration (FDA)-cleared system for administration of 18F-FDG and 18F-NaF. Intego infuses doses on-demand, providing clinicians with greater flexibility, enhanced workflow, added protection and more accurate, repeatable, patient-specific dosing. Now, through distribution with Comecer, clinicians in Europe and other markets will have easier access to this radiation dose reducing technology.
For more information: www.comecer.com, www.healthcare.bayer.com
July 30, 2024 
